American Diabetes Association
Browse

Sleep Irregularity and the Incidence of Type 2 Diabetes: A Device-Based Prospective Study in Adults

Download (538.16 kB)
figure
posted on 2024-10-10, 16:24 authored by Jean-Philippe Chaput, Raaj Kishore Biswas, Matthew Ahmadi, Peter A. Cistulli, Angelo Sabag, Marie-Pierre St-Onge, Emmanuel Stamatakis

Objective: To prospectively examine the association between device-measured sleep regularity and incidence of type 2 diabetes (T2D) in a population-based sample of adults. We also examined if meeting sleep duration recommendations attenuates or eliminates the effects of irregular sleep on T2D.

Research Design and Methods: Prospective cohort study of adults aged 40-79 years participating in the UK Biobank accelerometer substudy. Participants wore wrist-attached accelerometers for a duration of 7 days, which was used to compute the Sleep Regularity Index (SRI). Participants were categorized as irregular (SRI <71.6), moderately irregular (SRI between 71.6 and 87.3), and regular (SRI >87.3) sleepers. T2D diagnosis was obtained through self-reports and health records.

Results: We analyzed data from 73,630 individuals followed for 8 years, without a previous history of T2D and without an event in the first year of follow-up. Compared to regular sleepers, irregular (HR: 1.38, 95%CI: 1.20-1.59) and moderately irregular sleepers (HR: 1.35, 95%CI: 1.19-1.53) were at higher risk of T2D incidence. Dose-response analyses treating SRI as a continuous measure showed higher T2D incidence with SRI scores below 80. Meeting current sleep duration recommendations did not counteract the adverse effects of irregular (HR: 1.35, 95%CI: 1.09-1.66) or moderately irregular (HR: 1.29, 95%CI: 1.08-1.54) sleep on T2D incidence.

Conclusions: Moderate and high sleep irregularity were deleteriously associated with T2D risk, even among participants who slept ≥7 hours/night. Future sleep interventions will need to pay more attention to the consistency in bedtimes and wake-up times, in addition to sleep duration and quality.


Funding

J.P.C. is supported by the Canadian Institutes of Health Research and the CHEO Research Institute. M.A. is funded by the National Heart Foundation (APP 107158). P.A.C. is funded by the Australian National Health and Medical Research Council through an Investigator Grant Level 3 (APP 2008157). M.P.S.O. is funded by the National Institutes of Health R01DK128154 and R35HL155670. ES is funded by an NHMRC Leadership level 2 fellowship (APP1194510). The funders had no role in the study design or implementation; data collection, management, analysis, or interpretation; manuscript preparation, review, or approval; or the decision to submit the manuscript for publication.

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC